{"id":3668,"date":"2020-05-18T14:12:41","date_gmt":"2020-05-18T06:12:41","guid":{"rendered":"https:\/\/www.ixensor.com\/ixensor_web\/?p=3668"},"modified":"2020-10-26T14:37:45","modified_gmt":"2020-10-26T06:37:45","slug":"ixensor-tackles-covid-19-two-testing-solutions-pipeline","status":"publish","type":"post","link":"https:\/\/www.ixensor.com\/ixensor_web\/ixensor-tackles-covid-19-two-testing-solutions-pipeline\/","title":{"rendered":"iXensor tackles COVID-19 with two testing solutions in the pipeline"},"content":{"rendered":"<p><b>TAIPEI, TAIWAN \u2013 May 18th, 2020<\/b><span style=\"font-weight: 400;\"> \u2013 <\/span><a href=\"https:\/\/www.ixensor.com\/ixensor_web\/\"><span style=\"font-weight: 400;\">iXensor Co., Ltd.<\/span><\/a><span style=\"font-weight: 400;\"> (6734.TWO).\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">On February 21st, 2020, iXensor formed the COMBAT project team to tackle the global COVID-19 pandemic challenge from the testing and digital solution perspective, aiming to aid <\/span><span style=\"font-weight: 400;\">the<\/span><span style=\"font-weight: 400;\"> early detection of COVID-19 infection<\/span><span style=\"font-weight: 400;\">s<\/span><span style=\"font-weight: 400;\">. Two state-of-the-art antigen-based testing solutions are in the development stage.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Our team has been working <\/span><span style=\"font-weight: 400;\">relentlessly hard<\/span><span style=\"font-weight: 400;\"> on both sides of the Pacific Ocean with 15 hours time difference to strategize solutions aggressively.\u00a0 Building on top of our strength in integrating medical engineering, biochemistry, and information technology, we are developing an innovative molecular diagnostic solution that <\/span><span style=\"font-weight: 400;\">carries<\/span><span style=\"font-weight: 400;\"> iXensor&#8217;s DNA for being highly mobile and close to the patients. In this case, the target patients will be COVID-19 suspects, so authorities and employers can test, track, and isolate them accordingly.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Up to this point in time, we have two cutting-edge antigen-based testing solutions for both big-scale screening and precision diagnosing use cases in the development stage. We are looking forward to announcing our answers to this pandemic to the public soon and supporting the safe &#8220;Back to work&#8221; return of the global economy.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><b>About iXensor<\/b><\/p>\n<p><span style=\"font-weight: 400;\">iXensor is a new generation healthtech company that integrates optics, biochemistry, and information technology expertise to develop the PixoTech\u00ae platform for smarter healthcare. Based on this integrated technology, iXensor created PixoTest\u00ae, the world\u2019s first FDA-approved smartphone camera-based blood testing system in 2017, followed by a wide range of professional in-vitro diagnostics (IVD) under the PixoTest\u00ae POCT brand and OTC self-testing products under the Eveline\u00ae brand.<\/span><\/p>\n<p><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>Media Contact\u00a0<\/b><\/p>\n<p><span style=\"font-weight: 400;\">Contact Person: Patrick Liao<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Company URL: <a href=\"https:\/\/www.ixensor.com\/\">www.ixensor.com<\/a><\/span><\/p>\n<p><span style=\"font-weight: 400;\">Email: <\/span><a href=\"mailto:pr@ixensor.com\"><span style=\"font-weight: 400;\">pr@ixensor.com<\/span><\/a><\/p>\n<p><span style=\"font-weight: 400;\">Phone: +886-2-8751-1335 ext.205<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>TAIPEI, TAIWAN \u2013 May 18th, 2020 \u2013 iXensor Co., Ltd. (6734.TWO).\u00a0 On February 21st, 2020, iXensor formed the COMBAT project team to tackle the global COVID-19 pandemic challenge from the testing and digital solution perspective, aiming to aid the early detection of COVID-19 infections. Two state-of-the-art antigen-based testing solutions are&#8230;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[25],"tags":[41,39,40],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>iXensor tackles COVID-19 with two testing solutions in the pipeline | iXensor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ixensor.com\/ixensor_web\/ixensor-tackles-covid-19-two-testing-solutions-pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"iXensor tackles COVID-19 with two testing solutions in the pipeline | iXensor\" \/>\n<meta property=\"og:description\" content=\"TAIPEI, TAIWAN \u2013 May 18th, 2020 \u2013 iXensor Co., Ltd. (6734.TWO).\u00a0 On February 21st, 2020, iXensor formed the COMBAT project team to tackle the global COVID-19 pandemic challenge from the testing and digital solution perspective, aiming to aid the early detection of COVID-19 infections. Two state-of-the-art antigen-based testing solutions are...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ixensor.com\/ixensor_web\/ixensor-tackles-covid-19-two-testing-solutions-pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"iXensor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/IXensor\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-05-18T06:12:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-10-26T06:37:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/s3-us-west-1.amazonaws.com\/ix-us-west-1\/ixensor_web\/wp-content\/uploads\/2018\/01\/03165927\/POCT_GLU_Products-1.png\" \/>\n<meta name=\"author\" content=\"nicola\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"nicola\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.ixensor.com\/ixensor_web\/ixensor-tackles-covid-19-two-testing-solutions-pipeline\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ixensor.com\/ixensor_web\/ixensor-tackles-covid-19-two-testing-solutions-pipeline\/\"},\"author\":{\"name\":\"nicola\",\"@id\":\"https:\/\/www.ixensor.com\/ixensor_web\/?lang=zh-hant\/#\/schema\/person\/4518ff81b6d4f903667c0ec1bedef2cd\"},\"headline\":\"iXensor tackles COVID-19 with two testing solutions in the pipeline\",\"datePublished\":\"2020-05-18T06:12:41+00:00\",\"dateModified\":\"2020-10-26T06:37:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ixensor.com\/ixensor_web\/ixensor-tackles-covid-19-two-testing-solutions-pipeline\/\"},\"wordCount\":281,\"publisher\":{\"@id\":\"https:\/\/www.ixensor.com\/ixensor_web\/?lang=zh-hant\/#organization\"},\"keywords\":[\"Antigen\",\"COVID19\",\"Testing\"],\"articleSection\":[\"News Release\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ixensor.com\/ixensor_web\/ixensor-tackles-covid-19-two-testing-solutions-pipeline\/\",\"url\":\"https:\/\/www.ixensor.com\/ixensor_web\/ixensor-tackles-covid-19-two-testing-solutions-pipeline\/\",\"name\":\"iXensor tackles COVID-19 with two testing solutions in the pipeline | iXensor\",\"isPartOf\":{\"@id\":\"https:\/\/www.ixensor.com\/ixensor_web\/?lang=zh-hant\/#website\"},\"datePublished\":\"2020-05-18T06:12:41+00:00\",\"dateModified\":\"2020-10-26T06:37:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ixensor.com\/ixensor_web\/ixensor-tackles-covid-19-two-testing-solutions-pipeline\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ixensor.com\/ixensor_web\/ixensor-tackles-covid-19-two-testing-solutions-pipeline\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ixensor.com\/ixensor_web\/ixensor-tackles-covid-19-two-testing-solutions-pipeline\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9801\",\"item\":\"https:\/\/www.ixensor.com\/ixensor_web\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"iXensor tackles COVID-19 with two testing solutions in the pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ixensor.com\/ixensor_web\/?lang=zh-hant\/#website\",\"url\":\"https:\/\/www.ixensor.com\/ixensor_web\/?lang=zh-hant\/\",\"name\":\"iXensor\",\"description\":\"The Pioneer of Mobile Health\",\"publisher\":{\"@id\":\"https:\/\/www.ixensor.com\/ixensor_web\/?lang=zh-hant\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ixensor.com\/ixensor_web\/?lang=zh-hant\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ixensor.com\/ixensor_web\/?lang=zh-hant\/#organization\",\"name\":\"iXensor\",\"url\":\"https:\/\/www.ixensor.com\/ixensor_web\/?lang=zh-hant\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ixensor.com\/ixensor_web\/?lang=zh-hant\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/d2vuifx12zlp8h.cloudfront.net\/ixensor_web\/wp-content\/uploads\/2021\/04\/14110143\/iXensor_Logo2.svg\",\"contentUrl\":\"https:\/\/d2vuifx12zlp8h.cloudfront.net\/ixensor_web\/wp-content\/uploads\/2021\/04\/14110143\/iXensor_Logo2.svg\",\"width\":126,\"height\":28,\"caption\":\"iXensor\"},\"image\":{\"@id\":\"https:\/\/www.ixensor.com\/ixensor_web\/?lang=zh-hant\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/IXensor\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ixensor.com\/ixensor_web\/?lang=zh-hant\/#\/schema\/person\/4518ff81b6d4f903667c0ec1bedef2cd\",\"name\":\"nicola\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ixensor.com\/ixensor_web\/?lang=zh-hant\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/663504446d449a3c52c7cd02f1c3d5c7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/663504446d449a3c52c7cd02f1c3d5c7?s=96&d=mm&r=g\",\"caption\":\"nicola\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"iXensor tackles COVID-19 with two testing solutions in the pipeline | iXensor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ixensor.com\/ixensor_web\/ixensor-tackles-covid-19-two-testing-solutions-pipeline\/","og_locale":"en_US","og_type":"article","og_title":"iXensor tackles COVID-19 with two testing solutions in the pipeline | iXensor","og_description":"TAIPEI, TAIWAN \u2013 May 18th, 2020 \u2013 iXensor Co., Ltd. (6734.TWO).\u00a0 On February 21st, 2020, iXensor formed the COMBAT project team to tackle the global COVID-19 pandemic challenge from the testing and digital solution perspective, aiming to aid the early detection of COVID-19 infections. Two state-of-the-art antigen-based testing solutions are...","og_url":"https:\/\/www.ixensor.com\/ixensor_web\/ixensor-tackles-covid-19-two-testing-solutions-pipeline\/","og_site_name":"iXensor","article_publisher":"https:\/\/www.facebook.com\/IXensor\/","article_published_time":"2020-05-18T06:12:41+00:00","article_modified_time":"2020-10-26T06:37:45+00:00","og_image":[{"url":"https:\/\/s3-us-west-1.amazonaws.com\/ix-us-west-1\/ixensor_web\/wp-content\/uploads\/2018\/01\/03165927\/POCT_GLU_Products-1.png"}],"author":"nicola","twitter_card":"summary_large_image","twitter_misc":{"Written by":"nicola","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ixensor.com\/ixensor_web\/ixensor-tackles-covid-19-two-testing-solutions-pipeline\/#article","isPartOf":{"@id":"https:\/\/www.ixensor.com\/ixensor_web\/ixensor-tackles-covid-19-two-testing-solutions-pipeline\/"},"author":{"name":"nicola","@id":"https:\/\/www.ixensor.com\/ixensor_web\/?lang=zh-hant\/#\/schema\/person\/4518ff81b6d4f903667c0ec1bedef2cd"},"headline":"iXensor tackles COVID-19 with two testing solutions in the pipeline","datePublished":"2020-05-18T06:12:41+00:00","dateModified":"2020-10-26T06:37:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ixensor.com\/ixensor_web\/ixensor-tackles-covid-19-two-testing-solutions-pipeline\/"},"wordCount":281,"publisher":{"@id":"https:\/\/www.ixensor.com\/ixensor_web\/?lang=zh-hant\/#organization"},"keywords":["Antigen","COVID19","Testing"],"articleSection":["News Release"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.ixensor.com\/ixensor_web\/ixensor-tackles-covid-19-two-testing-solutions-pipeline\/","url":"https:\/\/www.ixensor.com\/ixensor_web\/ixensor-tackles-covid-19-two-testing-solutions-pipeline\/","name":"iXensor tackles COVID-19 with two testing solutions in the pipeline | iXensor","isPartOf":{"@id":"https:\/\/www.ixensor.com\/ixensor_web\/?lang=zh-hant\/#website"},"datePublished":"2020-05-18T06:12:41+00:00","dateModified":"2020-10-26T06:37:45+00:00","breadcrumb":{"@id":"https:\/\/www.ixensor.com\/ixensor_web\/ixensor-tackles-covid-19-two-testing-solutions-pipeline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ixensor.com\/ixensor_web\/ixensor-tackles-covid-19-two-testing-solutions-pipeline\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ixensor.com\/ixensor_web\/ixensor-tackles-covid-19-two-testing-solutions-pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9801","item":"https:\/\/www.ixensor.com\/ixensor_web\/"},{"@type":"ListItem","position":2,"name":"iXensor tackles COVID-19 with two testing solutions in the pipeline"}]},{"@type":"WebSite","@id":"https:\/\/www.ixensor.com\/ixensor_web\/?lang=zh-hant\/#website","url":"https:\/\/www.ixensor.com\/ixensor_web\/?lang=zh-hant\/","name":"iXensor","description":"The Pioneer of Mobile Health","publisher":{"@id":"https:\/\/www.ixensor.com\/ixensor_web\/?lang=zh-hant\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ixensor.com\/ixensor_web\/?lang=zh-hant\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ixensor.com\/ixensor_web\/?lang=zh-hant\/#organization","name":"iXensor","url":"https:\/\/www.ixensor.com\/ixensor_web\/?lang=zh-hant\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ixensor.com\/ixensor_web\/?lang=zh-hant\/#\/schema\/logo\/image\/","url":"https:\/\/d2vuifx12zlp8h.cloudfront.net\/ixensor_web\/wp-content\/uploads\/2021\/04\/14110143\/iXensor_Logo2.svg","contentUrl":"https:\/\/d2vuifx12zlp8h.cloudfront.net\/ixensor_web\/wp-content\/uploads\/2021\/04\/14110143\/iXensor_Logo2.svg","width":126,"height":28,"caption":"iXensor"},"image":{"@id":"https:\/\/www.ixensor.com\/ixensor_web\/?lang=zh-hant\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/IXensor\/"]},{"@type":"Person","@id":"https:\/\/www.ixensor.com\/ixensor_web\/?lang=zh-hant\/#\/schema\/person\/4518ff81b6d4f903667c0ec1bedef2cd","name":"nicola","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ixensor.com\/ixensor_web\/?lang=zh-hant\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/663504446d449a3c52c7cd02f1c3d5c7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/663504446d449a3c52c7cd02f1c3d5c7?s=96&d=mm&r=g","caption":"nicola"}}]}},"_links":{"self":[{"href":"https:\/\/www.ixensor.com\/ixensor_web\/wp-json\/wp\/v2\/posts\/3668"}],"collection":[{"href":"https:\/\/www.ixensor.com\/ixensor_web\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ixensor.com\/ixensor_web\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ixensor.com\/ixensor_web\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ixensor.com\/ixensor_web\/wp-json\/wp\/v2\/comments?post=3668"}],"version-history":[{"count":4,"href":"https:\/\/www.ixensor.com\/ixensor_web\/wp-json\/wp\/v2\/posts\/3668\/revisions"}],"predecessor-version":[{"id":3690,"href":"https:\/\/www.ixensor.com\/ixensor_web\/wp-json\/wp\/v2\/posts\/3668\/revisions\/3690"}],"wp:attachment":[{"href":"https:\/\/www.ixensor.com\/ixensor_web\/wp-json\/wp\/v2\/media?parent=3668"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ixensor.com\/ixensor_web\/wp-json\/wp\/v2\/categories?post=3668"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ixensor.com\/ixensor_web\/wp-json\/wp\/v2\/tags?post=3668"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}